Soluble Epoxide Hydrolase Derived Linoleic Acid Oxylipins, Small Vessel Disease Markers, and Neurodegeneration in Stroke

December 2022
Journal: Journal of the American Heart Association
Lead Author: Di Yu

All Authors: Di Yu, Nuanyi Liang, Julia Zebarth, Qing Shen, Miracle Ozzoude, Maged Goubran, Jennifer S. Rabin, Joel Ramirez, Christopher J. M. Scott, Fuqiang Gao, Robert Bartha, Sean Symons, Seyyed Mohammad Hassan Haddad, Courtney Berezuk, Brian Tan, Donna Kwan, Robert A. Hegele, Allison A. Dilliott, Nuwan D. Nanayakkara, Malcolm A. Binns, Derek Beaton, Stephen R. Arnott, Jane M. Lawrence‐Dewar, Ayman Hassan, Dar Dowlatshahi, Jennifer Mandzia, Demetrios Sahlas, Leanne Casaubon, Gustavo Saposnik, Yurika Otoki, Krista L. Lanctôt, Mario Masellis, Sandra E. Black, Richard H. Swartz, Ameer Y. Taha and Walter Swardfager, and The ONDRI Investigators


Trajectories of health system use and survival for community-dwelling persons with dementia a cohort study

Cerebral small vessel disease is associated with higher ratios of soluble‐epoxide hydrolase derived linoleic acid diols to their parent epoxides; however, the relationship had not yet been examined in stroke. This study helped determine that linoleic acid markers of cytochrome P450/soluble‐epoxide hydrolase activity were associated with small versus large vessel stroke. The findings may indicate a novel modifiable risk factor for small vessel disease and related neurodegeneration.